Les informations présentées dans l’Outil de recherche personnalisé d’essais cliniques de Myélome Canada sont issues de la base de données des essais cliniques internationaux du site ClinicalTrials.gov, répertoriées par la U.S. National Library of Medicine. Bien que le menu soit en français, les détails des études ne sont offerts qu’en anglais.
Mot de passe oublié?
Mot de passe oublié?

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

*Les informations de l'essai contenues sur cette page ont été récupérées du site ClinicalTrials.gov. Cliquez ici pour voir cet essai sur ClinicalTrials.gov.

Retour à la recherche
Imprimer l'étude
Titre complet:
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)
Stade ou Condition:
Multiple Myeloma
Phase d'étude:
Phase 3
Résumé:
The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).
Description détaillée:
Non disponible
Traitements:
Drug : Iberdomide

Specified dose on specified days

Drug : Lenalidomide

Specified dose on specified days

Groupes d'étude:
Experimental : Arm A1: Iberdomide Dose 1
Experimental : Arm A2: Iberdomide Dose 2
Experimental : Arm A3: Iberdomide Dose 3
Active Comparator : Arm B: Lenalidomide
Type d'étude:
Interventional
Protocole de l'étude:
Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Masking: None (Open Label)
Statut du recrutement:
En cours
Critères d'admissibilités:
sion Criteria
  • Confirmed diagnosis of symptomatic multiple myeloma (MM).
  • Eastern Cooperative Oncology Group performance status (ECOG) score of 0, 1, or 2.
  • Received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (PI) and immunomodulatory (IMiD) [eg, bortezomib thalidomide and dexamethasone (VTd), lenalidomide, bortezomib and dexamethasone (RVd)] with or without a CD38 monoclonal antibody, or Velcade® (bortezomib), cyclophosphamide, dexamethasone (VCd), and followed by a single or tandem autologous stem cell transplantation (ASCT). Post-stem cell transplant consolidation is permitted.
  • Participants within 12 months from initiation of induction therapy who achieved at least a partial response (PR) after autologous stem cell transplantation (ASCT) with or without consolidation, according to International Myeloma Working Group (IMWG 2016) criteria. Exclusion Criteria
  • Progressive disease or clinical relapse (as defined by IMWG response criteria) following ASCT with or without consolidation or is not responsive to primary therapy.
  • Smoldering myeloma, solitary plasmacytoma or nonsecretory myeloma.
  • Known central nervous system/meningeal involvement of MM.
  • Prior history of malignancies, other than MM, unless the participant has been free of the disease for ≥ 5 years.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
    • Lieux / Centres:

    Cross Cancer Institute, Edmonton, Alberta – En cours

    The Ottawa Hospital - General Campus, Ottawa, Ontario – En cours

    Local Institution - 0307, Montreal, Quebec – À venir

    CHUQ - The Hôtel-Dieu de Québec, Quebec, – En cours

    Contacts:
    Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
    Phone: 855-907-3286
    Email: [email protected]
    Publications:
    ???
    Date d’affichage:
    2023-04-24
    Date de début:
    June 22, 2023
    Dernière mise à jour:
    2024-05-06
    Nombre d'inscriptions anticipées:
    1216
    Date de fin prévue:
    2036-01-01
    Date de fin prévue de l'étude primaire:
    2029-03-15
    Condition:
    Multiple Myeloma
    Genre:
    All
    Âge:
    18 Years-N/A
    Accepte des bénévoles en santé:
    No
    Pays participants:
    Argentina
    Australia
    Austria
    Belgium
    Brazil
    Canada
    Chile
    China
    Colombia
    Czechia
    Denmark
    Finland
    France
    Germany
    Greece
    Hong Kong
    India
    Israel
    Italy
    Japan
    Korea, Republic of
    Mexico
    Netherlands
    Poland
    Portugal
    Romania
    Singapore
    Spain
    Sweden
    Switzerland
    Taiwan
    Turkey
    United Kingdom
    United States
    Numéro d’identification:
    NCT05827016
    Autres numéros d'identification de l'étude:
    IM048-022
    Comité de suivi des données:
    Yes
    Produit réglementé par la FDA (É-U):
    Yes
    IPD Sharing Statement :
    ???
    Responsables de l’étude:
    Sponsor
    Commanditaires de l’étude:
    lead_sponsor
    Bristol-Myers Squibb
    Industry
    Collaborators:
    ???
    Chercheurs:
    Bristol-Myers Squibb Bristol-Myers Squibb
    Protocol Registration and Results System:
    ???
    Date de vérification:
    2024-05-01